FGF2 Inhibitors |
Phase II study of low dose Pegintron (PEG interferon alfa-2b) in patients with metastatic melanoma over-expressing FGF2 (NCT00049530) |
32 |
Sept 2003 / not recruiting - ongoing |
Enzon Pharmaceuticals (Piscataway, NJ) |
Eastern Cooperative Oncology Group (Boston, MA) |
FGF2 inhibitor, interferon alpha stimulant |
Interventional, response level of suppression of plasma FGF2 level with low dose Pegintron |
Phase I, open-label, dose-finding study of FP-1039 in advanced solid tumors (NCT00687505) |
39 |
July 2008 / completed |
Five Prime Therapeutics, Inc. (San Francisco, CA) |
FGFR1 inhibitor |
Interventional, assess safety and tolerability |
Non-Specific Tyrosine Kinase Inhibitors |
Phase I dose escalation study of Lenvima (Lenvatinib) in patients with solid tumors (NCT00280397) |
27 |
Jan 2006 – Nov 2008 / completed |
Eisai Inc. (Japan) |
PDGFR-beta inhibitor; c-kit inhibitor; FGFR inhibitor; VEGFR 1-3 inhibitor |
Interventional; adverse events, safety, tolerability |
Phase Ib/II, open-label, multicenter study of Lenvima (lenvatinib) alone, and in combination with Everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment (NCT01136733) |
180 |
Aug 2010 / not recruiting - ongoing |
Eisai Co. Ltd. (Japan) |
PDGFR-b antagonist; VEGFR-2 antagonist, FGFR inhibitor |
Interventional, assess the dose-limiting and maximally tolerated toxicity, recommended dose, progression-free survival |
Phase II, multicenter, randomized, open-label study of Votrient (Pazopanib) in thyroid carcinoma (NCT01813136) |
168 |
Mar 2013 / ongoing - recruiting |
Centre Leon Berard (France) |
GlaxoSmithKline (Philadelphia, PA) |
PDGFR antagonist; BRAF inhibitor; c-kit inhibitor; VEGFR 1-3 antagonist |
Interventional, efficacy (objective response rate) |
Phase I/II study of Orantinib for advanced hepatocellular carcinoma (NCT00784290) |
35 |
Sept 2003 / completed |
Pfizer (New York City, NY) |
Taiho Pharmaceutical Co., Ltd. (Japan) |
FGF inhibitor; PDGF inhibitor; VEGFR-2 antagonist |
Interventional, assess the safety and response rate |
Phase II study of Dovitinib in patients with gastrointestinal stromal tumors refractory and/or Intolerant to Imatinib (NCT01478373) |
150 |
Jan 2012 - July 2014 / completed |
Novartis (East Hanover, NJ) |
FGF2 inhibitor; PDGFR Δ inhibitor; VEGFR inhibitor |
Interventional, measure safety and efficacy |
Phase II, open-label study of Lucitanib in patients with FGFR1-driven lung cancer (NCT02109016) |
40 |
Apr 2014/ recruiting - ongoing |
Advenchen Laboratories (Moorpark, CA) |
Clovis Oncology, Inc. (Boulder, CO) |
FGFR 1-3 inhibitor; VEGFR1-3 inhibitor |
Interventional, efficacy (objective response rate) |
Phase II study of Vargatef (Nintedanib) in patients with advanced FGFR3 mutated, overexpressed, or wild type urothelial carcinoma of urinary bladder (NCT02278978) |
129 |
Oct 2014/not recruiting - ongoing |
Boehringer Ingelheim (Germany) |
National Taiwan University Hospital (Taiwan) |
PDGFR α-Δ inhibitor; FGFR 1-3 inhibitor; VEGFR 1-3 inhibitor |
Interventional, safety study with primary purpose of treatment |
Phase I/II, multicenter, randomized, double-blind study of Vargatef (Nintedanib) in combination with paclitaxel for treatment of patients with BRAF wild-type metastatic melanoma (NCT02308553) |
126 |
Jan 2015 / ongoing - recruiting |
Boehringer Ingelheim (Ridgefield, CT) |
Prof. Dr.Dirk Schadendorf (Germany) |
PDGFR-alpha/beta inhibitor; FGFR1-3 inhibitor; VEGF1/2 inhibitor |
Interventional, measure of progression-free survival, safety, tolerability |
Phase III study to compare efficacy and safety of Masitinib in combination with Bortezomib and Dexamethasone to placebo in combination with Bortezomib and Dexamethasone in patients with relapsing multiple myeloma (NCT01470131) |
300 |
Apr 2013 |
Masitinib: AB Science (France) |
Masitinib: AB Science (France) |
FGFR modulator; PDGFR antagonist |
Interventional, assess overall time to progression and overall survival |
Bortezomib: Millennium Pharmaceuticals (Cambridge, MA) |
Immunomodulator; proteasome inhibitor |
Dexamethasone: Allergan (Ireland) |
Glucocorticoid receptor agonist |
FGFR Inhibitors |
Phase I, multicenter, open label study of oral Debio 1347 (CH5183284) in patients with advanced solid malignancies, whose tumors have an alteration of the FGFR 1, 2 or 3 genes (NCT01948297) |
112 |
Aug 2013 / ongoing - recruiting |
Chugai Pharmaceutical (Japan) |
Debiopharm International SA (Switzerland) |
Interventional, measure of safety and tolerability in dose escalation study |
Phase I, open-label, multicenter study of AZD4547 in patients with advanced solid tumors (NCT00979134) |
979 |
Oct 2009 / not recruiting, ongoing |
AstraZeneca (England) |
FGFR inhibitor |
Investigate the safety, tolerability and maximum tolerated dose |
Study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumors (NCT01795768) |
49 |
Sept 2012 / ongoing - recruiting |
Royal Marsden NHS Foundation Trust (England) |
FGFR inhibitor |
Interventional, assess efficacy within 8 weeks |
Phase I, multi-center, open-label, dose escalation study of oral BGJ398, in adult patients with advanced solid malignancies (NCT01004224) |
190 |
Dec 2009 / ongoing - recruiting |
Novartis (East Hanover, NJ) |
FGFR inhibitor |
Interventional, safety, tolerability, pharmacokinetics, pharmacodynamics |
Phase I study of JNJ-42756493 in subjects with advanced or refractory solid tumors or lymphoma (NCT01703481) |
260 |
Jun 2012 / ongoing - recruiting |
Astex Therapeutic (England) |
Janssen Research & Development, LLC (Belgium) |
FGFR inhibitor |
Interventional, safety, tolerability, pharmacokinetics, pharmacodynamics |
Phase I dose escalation study of ARQ 087 in adult subjects with advanced solid tumors (NCT01752920) |
120 |
Dec 2012 / ongoing - recruiting |
ArQule (Woburn, MA) |
FGFR inhibitor |
Interventional, measure of safety and tolerability |
Phase I study of LY2874455 in patients with advanced cancer (NCT01212107) |
94 |
Dec 2010 – Feb 2015 / completed |
Eli Lilly and Company (Indianopolis, IN) |
FGFR inhibitor |
Interventional, measure of safety and tolerability |
Phase I study of TAS-120 in patients with advanced solid tumors with or without FGF/FGFR-Related abnormalities followed by a Phase II study in patients with advanced solid tumors or multiple myeloma with FGF/FGFR-related abnormalities (NCT02052778) |
835 |
July 2014 / ongoing - recruiting |
Taiho Oncology, Inc. (Japan) |
FGFR inhibitor |
Interventional, measure of safety and tolerability |
Phase I, multicenter, open-label study of MFGR1877S in patients with relapsed or refractory multiple myeloma (NCT01122875) |
14 |
Nov 2010 – May 2012 / completed |
Genentech, Inc. (South San Francisco, CA) |
FGFR3 inhibitor |
Interventional, measure of safety and tolerability |
Phase I, open-label, dose-escalation study of BAY 1179470 in subjects with advanced, refractory solid tumors (NCT01881217) |
63 |
June 2013 / recruiting - ongoing |
Bayer (Whippany, NJ) |
FGFR2 inhibitor |
Interventional, measure of safety, tolerability, pharmacokinetics, and pharmacodynamics |